Kromek Group plc designs, develops, and manufactures x-ray and gamma ray detection and imaging, and radiation detection products for security screening, civil nuclear, and medical imaging markets in the United Kingdom, North America, South America, the Middle East, Asia, Europe, and Australasia. Its nuclear detection products include CPG, a CZT-based room temperature and high-resolution radiation detector; Kromek GR1, a gamma ray spectrometer; GR1-A, a USB-powered gamma spectrometer; SIGMA, a technology platform for scintillator products; TN15, a sensitivity thermal neutron scintillation detector; RENA-Mini, a platform for the development of pixelated detectors; Q4-GR1, a solution for mobile...
Thomas Wright Way
Sedgefield, TS21 3FD
Founded in 2003
Kromek Wins Six New Contract Across All Business Segments
Oct 17 16
Kromek announced that it has won six new contracts totaling approximately $3.1 million from new and existing customers including the US Defense Threat Reduction Agency (DTRA) and the UK Ministry of Defence. The contracts awarded were across all business segments and are expected be delivered over the next 6-24 months. Kromek has been awarded a $1.6 million two-year agreement by the US Defense Threat Reduction Agency, subject to final contract, to build on, and further enhance, the Group's technology platform to develop a ruggedised high performance isotope radiation detector capable of use in military and other harsh environments.
Kromek Group plc, Annual General Meeting, Sep 21, 2016
Aug 26 16
Kromek Group plc, Annual General Meeting, Sep 21, 2016, at 10:00 US Eastern Standard Time. Location: NETPark, North East Technology Park, Thomas Wright Way, Sedgefield, County Durham, TS21 3FD United Kingdom
Kromek Group plc Announces Consolidated Audited Earnings Results for the Year Ended April 30, 2016
Jul 19 16
Kromek Group plc announced consolidated audited earnings results for the year ended April 30, 2016. For the year, the company reported revenues of £8,342,000 compared with £8,101,000 for the same period a year ago. LBT was £4,143,000 compared with £3,135,000 for the same period a year ago. EBITDA was £2,523,000 compared with £1,680,000 for the same period a year ago. Adjusted EBITDA was £2,376,000 compared with £1,559,000 for the same period a year ago. Operating loss was £4,060,000 compared with £3,064,000 for the same period a year ago. Loss for the year from continuing operations was £2,151,000 or 1.5 pence per diluted share compared with £2,146,000 or 2.0 pence per diluted share for the same period a year ago. Loss for the year was £2,151,000 compared with £2,146,000 for the same period a year ago. Net cash used in operating activities was £2,845,000 compared with £2,361,000 for the same period a year ago. Purchase of property, plant and equipments was £444,000 compared with £2,558,000 for the same period a year ago. Purchases of patents and trademarks was £320,000 compared with £368,000 for the same period a year ago. Capitalisation of development costs was £2,819,000 compared with £1,812,000 for the same period a year ago.